# Chemical and Biological Mechanisms Relevant to the Rescue of MG-132-Treated Neurons by Cysteine

## TL;DR

This study investigates how cysteine protects neurons from MG-132, a proteasome inhibitor, and finds that it acts as an antioxidant rather than chemically inactivating the drug.

## Contribution

The study clarifies the mechanism of cysteine's neuroprotection against MG-132, challenging previous assumptions about chemical inactivation.

## Key findings

- L-cysteine reacts with MG-132 to form a stable product, but does not fully inactivate it in cellular models.
- Glutathione and N-acetyl-cysteine do not reduce proteasome inhibition by MG-132, even at high concentrations.
- Cysteine's protective effect is likely due to antioxidant activity rather than chemical inactivation of MG-132.

## Abstract

Proteasome dysfunctions are observed in many human pathologies. To study their role and potential treatment strategies, models of proteasome inhibition are widely used in biomedical research. One frequently used tool is the proteasome inhibitor MG-132. It triggers the degeneration of human neurons, and several studies show protection from pathological events by glutathione or its precursors. It has therefore been concluded that glutathione protects cells from proteasome dysfunction. However, an alternative explanation is that MG-132, which is a peptide aldehyde, is chemically inactivated by thiols, and the apparent protection by glutathione from proteasome dysfunction is an artefact. To clarify this issue, we examined the chemical inactivation of MG-132 by thiols and the role of such reactions for neuroprotection. Using mass spectrometry and nuclear magnetic resonance spectroscopy, we found that MG-132 reacted with L-cysteine to form a stable end product and with glutathione to form an unstable intermediate. Using a cell-free proteasome inhibition assay, we found that high concentrations of L-cysteine can scavenge a substantial fraction of MG-132 and thus reduce proteasome inhibition. Glutathione (or N-acetyl-cysteine) did not alter proteasome inhibition (even at high concentrations). In a final step, we studied human neuronal cultures. We exposed them to MG-132, supplemented the culture medium with various thiols, and assessed intracellular L-cysteine concentrations. The transcriptome response pattern also indicated an inhibition of the proteasome by MG-132 in the presence of L-cysteine. We conclude that thiol concentrations that can be reached in cells do not inactivate MG-132 in pathological models. They rather act in a cytoprotective way as antioxidants.